

EVIDENCE FOR HPV73 AS AN ETIOLOGICAL AGENT FOR INVASIVE CERVICAL CANCER



INTRODUCTION

More than 40 genotypes of HPV have been found to infect the genital mucosa and 12 (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are characterized as high-risk types (HR-HPV) for invasive cervical cancer (ICC) according to the International Agency for Research on Cancer. However, due to their low prevalence in ICC and lack of evidence of biological data, eight HPV types have been classified as probably (HPV68) or possibly (HPV26, 53, 66, 67, 70, 73, and 82) HR-HPV. Identification and characterization of the biology of rare carcinogenic HPV types is important to support the programs of HPV screening and vaccination, and to understanding the basis of HPV carcinogenicity.

594 ICC Biopsies from INCA - Rio de Janeiro

METHODS

Transcriptional activity

RNA -> cDNA -> assessing transcripts by PCR: Size & Sequencing

Montefiore

GOALS

HPV type

To provide molecular evidence for the carcinogenic role of HPV73 in invasive cervical cancer (ICC). HPV73 is neither routinely evaluated in HPV screening, nor included in any of the prophylactic vaccines.



16*	370	62.3
18*	77	13.0
45*	33	5.6
35	12	2.0
58*	11	1.9
52*	8	1.3
73	8	1.3
31*	7	1.2
33*	7	1.2
39	6	1.0
59	6	1.0
26	2	0.3
51	2	0.3
56	2	0.3
68	2	0.3
83	1	0.2
Co-infection	20	3.4
Undetermined	20	3.4
Total	594	100.0

Ν

*Gardasil 9 FDA-approved HPV vaccine to HPV16,



Table 2. Summary of additional methods for confirmation of HPV73 single infection. Four of eight samples single infection was confirmed.

		DNA	
amples	Dot - Blot	HPV16	HPV18
1	73	-	-
2	73	+	-
3	73, 16	+	-
4	73	-	-

Figure 2. Transcriptional activity of HPV73 (E1^E4 and E6*) and HPV16 (E6*) was assessed by PCR of cDNA. Presence of HPV73 E1^E4 was observed in 04/08 samples (upper agarose gel), HPV73 E6* was observed in all samples (middle agarose gel). No transcripts of HPV16 (E6*) was observed (lower agarose gel). NC: negative control, NS: non-spliced form with HPV73 positive DNA.

Table 3. Summary of transcriptional activity of HPV73
 and HPV16

Sampla	DN	A	HPV7	3rna	HPV16RNA		
Sample	Dot -Blot	HPV16	E1^E4	E6*	E6*		
C 1	70						

Samplos	HPV73RNA	DNA					
Samples	E1^E4	E1a	E1b	E1c	E1d E	E2a	E2b
S1	+	+	+	+	+	+	+
S2	+	+	+	+	+	+	+
S3	-	+	+	+	-	-	-
S4 S5	+	+	+	+	+	+	+
	-	+	-	-	-	-	-
S6	-	+	+	+	+	-	-
S7	+	+	+	+	+	+	+
S8		+	+	-	-	-	+

In red are samples with disruption in E1/E2.

18, 31, 33, 45, 52, 58, 6 and 11. In red, HPV73 positive samples selected to analysis

55	/3, 58	+	-	
S6	73	-	-	
S7	73	+	-	
S8	73	_	-	

In red, samples with confirmation of single infection by all methodologies

CONCLUSION

S2	73	+	+	+	-
S3	73, 16	+	-	+	-
S4	73	-	+	+	-
S5	73, 58	+	-	+	-
S6	73	-	-	+	-
S7	73	+	+	+	-
S8	73	-	*	*	*

*No RNA available. In red, samples with presence of transcripts. No HPV16 transcripts were observed

SUPPORT

These data provide compelling evidence for the association of HPV73 and invasive cervix cancer, including:

- Single HPV73 type presence in cancer tissues
- Active HPV73 E6/E6* transcription in tumor tissue
- Disruption of HPV73 genome suggestive of integration

These results suggest that HPV73 should be considered carcinogenic. Additional studies in tumor tissues and screening specimens are warranted.







Projeto Gráfico: Serviço de Edição e Informação Técnico-Científica / INCA

SAÚDE



